Patent application number | Description | Published |
20100105613 | THERAPEUTIC AGENT FOR OCCLUSIVE PERIPHERAL VASCULAR DISEASE, AND USE THEREOF - A study was made on the therapeutic effect of midkine on an occlusive peripheral vascular disease, and it was found that midkine has an activity of promoting neovascularization and that a blood vessel can be proliferated and the blood flow in the upper and lower limbs can be improved (in other words, the condition of an ischemic disease in the upper and lower limbs can be ameliorated) by introducing midkine into a site affected by the occlusive peripheral vascular disease. | 04-29-2010 |
20100137564 | POLYPEPTIDE OF N-ACETYLGLUCOSAMINE-6-O-SULFOTRANSFERASE AND DNA ENCODING THE SAME - A polypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below:
| 06-03-2010 |
20100197577 | NITRIC OXIDE SYNTHASE ACTIVATOR - The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient. | 08-05-2010 |
20110059102 | Therapeutic Method Targeting Midkine - Provided is a therapeutic method targeting midkine for treating mammalian kidney disorders, primary kidney disorders, hypertension that follows secondary kidney disorders such as diabetic nephropathy, and hypertension secondary to chronic kidney disease. | 03-10-2011 |
20110111427 | BIOMARKER FOR THE ESTIMATION OF ACUTE RENAL DISORDER AND PROGNOSIS OF THE DISORDER, AND USE OF THE BIOMARKER - To provide a novel biomarker that is useful for prediction of early onset of acute kidney injury, estimation of prognosis associated with a renal function, and differentiation of acute kidney injury. Furthermore, to provide use of the novel biomarker. Midkine is used as a biomarker. The determination of a possibility of the onset of acute kidney injury, estimation of prognosis associated with a renal function or differentiation of an acute kidney injury are carried out based on the detection result of the urinary midkine. | 05-12-2011 |
20150203573 | MONOCLONAL ANTIBODY AGAINST HUMAN MIDKINE - A monoclonal antibody, which recognizes at least two amino acids among amino acids located at position 69, position 79, position 81 and position 102 of human midkine, has been found to have excellent reactivity with and excellent neutralizing activity against human midkine. Moreover, the activity of suppressing the proliferation of tumor has been observed in the antibody having excellent neutralizing activity. The use of the antibody of the present invention makes it possible to treat cancer effectively and to detect or purify midkine efficiently. | 07-23-2015 |
Patent application number | Description | Published |
20090047319 | Pharmaceutical composition for obstructive vascular disease - Provided is the excellent prevention or treatment of a vascular occlusive disease such as vascular restenosis. A pharmaceutical composition for a obstructive vascular disease comprising a nucleic acid construct capable of inhibiting the expression of a midkine gene through RNA interference and a collagen molecule. The use of the nucleic acid construct capable of inhibiting the expression of an MK protein through RNA interference in the presence of the collagen molecule can provide an excellent inhibitory effect on the thickened vascular intima. | 02-19-2009 |
20100056437 | Compositions for Treating or Preventing Myocardial Damage or Heart Failure - The present inventors compared myocardial damages after ischemia/reperfusion in wild-type mice and Midkine (MK)-deficient mice to confirm the effects and functions of MK. MK administration was found to significantly prevent cardiomyocyte apoptosis in both cultured cardiomyocytes (in vitro) and mouse models (in vivo). | 03-04-2010 |
20110059508 | IMPROVING AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND RHO KINASE ACTIVATION INHIBITOR - An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated. | 03-10-2011 |
20110125075 | METHOD FOR CONTROL OF ELECTROPORATION APPARATUS - A method for controlling an electroporation apparatus for use in an animal such as human and a non-human animal, the method comprising a step of applying a voltage to an electrode of the electroporation apparatus placed in/on a biological sample of the animal in the presence of a nucleic acid construct capable of inhibiting the expression of a gene in the animal. In this manner, a nucleic acid construct can be introduced into a cell of a living body with good efficiency. | 05-26-2011 |
20110275137 | IMPROVING AGENT FOR NEUROPATHIC PAIN - An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan. | 11-10-2011 |
20130164276 | AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND Rho KINASE ACTIVATION INHIBITOR - An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-β-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated. | 06-27-2013 |
20130230509 | AGENT FOR NEUROPATHIC PAIN - An object of the present invention is to provide a substance which can be used as an active ingredient for improving neuropathic pain having a novel mechanism of action different from those of currently available agents and, therefore, provide an improving agent for neuropathic pain which rarely interacts with currently available agents and also does not have adverse reactions similar to those of currently available agents. An improving agent for neuropathic pain due to a hyperalgesic response of the present invention as a means for resolution is characterized by comprising, as an active ingredient, a lyase (an elimination enzyme) which has an activity of degrading a chondroitin sulfate chain of a chondroitin sulfate proteoglycan, and is typified by chondroitinase ABC which selectively removes chondroitin sulfate and dermatan sulfate of a proteoglycan. | 09-05-2013 |